Christopher Wood, MD
Ophthalmology · Arlington Heights, ILNPI 1508880469
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,750 of the $29,032 with a category attached, or 68.0%. 30 manufacturers reported payments, led by Lumenis BE Inc at 34.1% of the total. Reporting peaked in 2019 at $10,257 and has fallen 54.6% since, to $4,652 in 2025. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $121.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$10K
- Lumenis Ltd.$7K
- Rxsight Inc$3K
- Lumenis, Inc$3K
- Alcon$1K
- AbbVie$847
- plus $4K from 24 others
What the payments were for
- Consulting fees$3,00010%
- Speaking & faculty fees$19,75068%
- Food & beverage$6,23721%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 2 | $9,900 |
| Lumenis Ltd. | 1 | $7,050 |
| Rxsight Inc | 11 | $3,189 |
| Lumenis, Inc | 2 | $2,800 |
| Alcon | 31 | $1,026 |
| AbbVie(2 entities) | 46 | $847 |
| Bausch & Lomb Americas Inc. | 27 | $763 |
| Harrow Eye, LLC | 11 | $706 |
| NEW World Medical,inc. | 11 | $515 |
| Novartis | 22 | $441 |
| Aerie Pharmaceuticals, Inc. | 9 | $247 |
| Oyster Point Pharma, Inc. | 12 | $227 |
| Amgen(2 entities) | 9 | $194 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $169 |
| Sun Pharmaceutical Industries Inc. | 7 | $158 |
| Tarsus Pharmaceuticals, Inc. | 6 | $134 |
| Iridex Corporation | 1 | $114 |
| Biotissue Holdings Inc. | 3 | $106 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $87 |
| Rayner Intraocular Lenses Limited | 3 | $79 |
| Ivantis, Inc | 3 | $58 |
| Thea Pharma Inc. | 3 | $48 |
| Beaver-visitec International, Inc. | 2 | $46 |
| AstraZeneca | 1 | $25 |
| Dompe US, Inc. | 1 | $21 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Glaukos Corporation | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Sight Sciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- M22$9,900
- LIGHT ADJUSTABLE LENS (LAL)$3,000
- RXSIGHT CONTACT LENS$3,000
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$3,000
- RXSIGHT INJECTOR HANDPIECE$3,000
- RXSIGHT INJECTOR CARTRIDGE$3,000
- AcrySof IQ PanOptix$147
- Clareon PanOptix Pro$127
- enVista MX60 IOL$111
- ARGOS$108
- Tecnis Multifocal Family of 1-piece IOLS$104
- DURYSTA$101
How this compares
$29,032 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 66 | $97,057 |
| LumiganBimatoprost | 81 | $47,765 |
| XiidraLifitegrast | 12 | $17,367 |
| RhopressaNetarsudil Mesylate | 26 | $10,913 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $10,655 |
| Cyclosporine | 12 | $6,083 |
| Latanoprost | 337 | $4,825 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $4,242 |
| Travoprost | 23 | $3,069 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 110 | $1,761 |
| Prednisolone Acetate | 43 | $1,691 |
| Ketorolac Tromethamine | 89 | $888 |
| ErythromycinErythromycin Base | 69 | $708 |
| Timolol Maleate | 47 | $590 |
| Brimonidine Tartrate | 24 | $423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $847 | $144,823147 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $247 | $21,56840 claims |
| Bausch & Lomb Americas Inc.Xiidra | $763 | $17,36712 claims |
| AlconSimbrinza | $1,026 | $4,24211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Arlington Heights
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.